drugset / Trial / NCT01643785

Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection

NCT01643785

Terminated 30 enrolled Chuncheon Sacred Heart Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of the second-line eradication therapy against Helicobacter pylori.

Timeline

Start
2012-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject pronase Protein / enzyme biologic 20000 iu
Background Esomeprazole Small molecule 40 mg
Background Lansoprazole Other / unclassified 30 mg
Background Metronidazole Small molecule 500 mg
Background Omeprazole Other / unclassified 20 mg
Background Pantoprazole Other / unclassified 40 mg
Background Rabeprazole Small molecule 20 mg
Background Tetracycline Unknown 500 mg
Background tripotassium dicitrate bismuthate Unknown 300 mg